Goutsouliak, Kristina
Veeraraghavan, Jamunarani http://orcid.org/0000-0002-9524-9487
Sethunath, Vidyalakshmi http://orcid.org/0000-0002-3308-3063
De Angelis, Carmine http://orcid.org/0000-0003-1158-4630
Osborne, C. Kent
Rimawi, Mothaffar F. http://orcid.org/0000-0002-4284-5656
Schiff, Rachel http://orcid.org/0000-0003-1696-5213
Article History
Accepted: 28 October 2019
First Online: 13 December 2019
Competing interests
: C.K.O. has received research funding from AstraZeneca and GlaxoSmithKline, has served on advisory boards for AstraZeneca, Genentech and Tolmar Pharmaceuticals, has been a data monitoring committee member for Eli Lilly, and is a stockholder of GeneTex. M.F.R. receives research support from GlaxoSmithKline via his institution and has been a consultant for Daiichi, Genentech, Macrogenics and Novartis. R.S. has received research funding from AstraZeneca, Gilead Sciences, GlaxoSmithKline and PUMA Biotechnology, and has been a consultant or advisory committee member for Eli Lilly and Macrogenics. The other authors declare no competing interests.